New white paper available
The mainstream news has certainly reduced its coverage of the Zika viral epidemic, but there’s still plenty happening that our community should be aware of. The Centers for Disease Control and Prevention (CDC) recently published results of a new study showing that Zika virus can replicate in placentas and in the fetal brain, shedding light on the severe birth defects associated with this virus. They also found that the virus persisted even seven months after the mother was infected.
The CDC has also been providing frequent updates on where Zika transmission is happening, with these maps of southern Florida featuring detailed information on risk of local infection. Meanwhile, five cases of probable mosquito-based infection have been reported in Texas in late 2016. According to the CDC’s tally as of early December, more than 4,500 cases of Zika infection have been reported in the U.S. (including Hawaii), with 185 of those acquired locally in Florida.
Like everyone else in the infectious diseases community, we have been keeping a very close eye on Zika virus since the epidemic first began in South America. In a new white paper, we recap what’s known about the history of the virus, its relationship to other flaviviruses, the confounding factor that presents for accurate diagnosis, and data on the ongoing outbreak. We also report results from a recent World Health Organization study of assays for the virus, which includes our xMAP® MultiFLEX™ Zika RNA Assay. We hope this white paper serves as a useful resource for anyone looking to get up to speed or learn more about the virus and related diagnostics.
Disclaimer: EUA – In Vitro Diagnostic Use Under Emergency Use Authorization. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization for use by authorized laboratories. This test has been authorized only for the detection of RNA from Zika virus and diagnosis of Zika virus infection, not for any other viruses or pathogens. This test in only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Luminex and xMAP are trademarks of Luminex Corporation, registered in the U.S. and other countries. MultiFLEX is a trademark of GenArraytion Inc.